Hematologic Disorders

Hematologic disorders are conditions found in the blood and blood forming organs. This includes blood cell cancers, genetic disorders, anemia, HIV related conditions, sickle cell disease, and complications do to chemotherapy treatment or transfusions.

Our hematology team leads clinical trials that evaluate effective treatments through medicines, compare new therapies against existing protocols, and study groups of patients with hematologic conditions to decrease pain and reduce patient’s dependency on current treatments.

Apixaban B0661037, A Randomized, Open-Label, Active Controlled, Safety and Extrapolated Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of a Venous Thromboembolic Event

Protocol ID: Pfizer Apixaban

Disease: Deep Vein Thrombosis

Who can participate?: Children 2 to <18 years of age at the time of consent (Age Groups 1 and 2)

Lead Researcher: Sarah H. O'Brien, MD

Exercise versus DDAVP in patients with mild hemophilia A-is one inferior to the  other and do they work additively in improving hemostasis?

Protocol ID: DDAVP-Exercise

Disease: Hemophilia A

Who can participate?:

Mild Hemophilia A

Ages >13 and <21

FVIII: C level of >6% to <25%

Lead Researcher: Riten Kumar, MD

ISTH Database and DNA Biorespository for Congenital Antithrombin Deficiency- pilot/feasibility study

Protocol ID: ISTH Database

Disease: Thrombosis

Who can participate?:

Ages 0-21 years

AT deficiency confirmed

Lead Researcher: Riten Kumar, MD

Biomarkers of Sickle Cell Lung Disease

Protocol ID: BOLD

Disease: Sickle Cell

Who can participate?: SCD patients < 19 years old of all genotypes

Lead Researcher: Benjamin T. Kopp, MD

Community Counts Surveillance study

Protocol ID: Community Counts

Disease: Multiple Bleeding Disorders

Who can participate?:

Lead Researcher: Amy L. Dunn, MD

Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children (the "Kids-DOTT" Trial)

Protocol ID: KidsDott

Disease: Thrombosis

Who can participate?: Children (birth to <21 years of age) with radiologically-confirmed acute venous thrombosis in the past 30 days

Lead Researcher: Sarah H. O'Brien, MD

My Life Our Future: A Hemophilia Genotyping Initiative Data and Sample Research Repository

Protocol ID: My Life Our Future

Disease: Hemophilia

Who can participate?:

Lead Researcher: Amy L. Dunn, MD

Single-dose study of oral rivaroxaban dry powder suspension formulation in children treated for thrombosis

Protocol ID: Rivaroxaban 17992 (Phase I)

Disease: Thrombosis

Who can participate?: Children with body weight 3 kg to <12 kg

Lead Researcher: Riten Kumar, MD

Sever Chronic Neutropenia International Registry Protocol

Protocol ID: SCN Registry

Disease: SCN

Who can participate?: Age greater than three months

Lead Researcher: Melissa J. Rose, DO

An Open-Label, Multicenter, Expanded Access Program for Emicizumab in Patients with Hemophilia A with Inhibitors

Protocol ID: ML39356

Disease: Hemophilia A

Who can participate?: Patients (adults and adolescents ≥ 12 years old) with hemophilia A with inhibitors against FVIII and who continue to have bleeds of any severity, despite treatment with currently available FDA-approved therapies, will comprise the population for this expanded access program

Lead Researcher: Amy L. Dunn, MD